|
Jun 29, 2009
|
Cordex Completes Production of ATPaceTM Clinical Trial Material
|
|
Jun 22, 2009
|
Cordex Signs European Development Partnership for ATPotentTM Sperm Motility Drug
|
|
Jun 2, 2009
|
Cordex Receives Special Protocol Assessment Approval from FDA for ATPaceTM
|
|
April 8, 2009
|
Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers
|
|
March 4, 2009
|
Cordex Pharma Files ATPace Formulation Patent
|
|
February 23, 2009
|
Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
|
|
February 18, 2009
|
Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace
|
|
February 13, 2009
|
Cordex Pharma Sets Fourth Quarter 2008 Program Update Call
|
|
February 11, 2009
|
Cordex Pharma Forms Heart Failure Medical Advisory Board
|
|
January 28, 2009
|
Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
|
|
January 23, 2009
|
Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29
|
|
November 20, 2008
|
Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
|
|
November 20, 2008
|
Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
|
|
November 18, 2008
|
Duska Therapeutics Sets Third Quarter 2008 Business Review and Program Update Call
|
|
November 10, 2008
|
Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
|
|
October 29, 2008
|
Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program
|
|
October 23, 2008
|
Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
|
|
August 21, 2008
|
Duska Therapeutics Provides Clinical Program Review and Reports Second Quarter 2008 Financial Results
|
|
August 19, 2008
|
Duska Therapeutics to Present at Noble Financial Equity 'M.A.D. MAX' Conference on Tuesday, August 19th at 1:30 p.m. PDT
|
|
August 12, 2008
|
Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace Protocol Synopsis
|
|
July 23, 2008
|
Duska Therapeutics Submits Phase 3 ATPace Protocol to FDA for Comment
|
|
June 26, 2008
|
Duska Therapeutics Obtains Standard & Poor's Listing
|
|
June 11, 2008
|
Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
|
|
June 9, 2008
|
Duska Therapeutics Retains Redington for Investor Relations
|
|
May 14, 2008
|
Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
|
|
April 25, 2008
|
Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace
|
|
April 15, 2008
|
Duska Therapeutics Sets Annual Meeting of Shareholders for June 27
|
|
April 2, 2008
|
Professor Riccardo Polosa Joins Duska Therapeutics' Scientific Advisory Board
|
|
March 11, 2008
|
Duska Therapeutics Plans Meeting with the FDA on ATPace
|
|
February 20, 2008
|
Duska Therapeutics to Present At Winter Global Equities Conference
|
|
February 7, 2008
|
Study Shows ATP Improves Motility of Sperm From Infertile Males
|
|
January 29, 2008
|
Duska Therapeutics Completes Corporate Relocation to La Jolla
|
|
November 13, 2007
|
Duska Therapeutics CEO Television Interview
|
|
November 1, 2007
|
Duska Therapeutics, Inc. Announces Engagement of RedChip Companies, Inc. to Lead Public and Investor Relations
|
|
October 31, 2007
|
Duska Therapeutics Appoints Dr. Alan J.Tuchman to the Board of Directors
|
|
October 18, 2007
|
Duska Therapeutics Appoints Shepard Goldberg and Steven Dinh as Board Directors
|
|
October 11, 2007
|
Duska Therapeutics Appoints H. David Coherd to the Board of Directors
|
|
October 3, 2007
|
Duska Therapeutics Names Dr. James S. Kuo as Chief Executive Officer
|
|
October 1, 2007
|
Duska Therapeutics Completes $5.75 Million Private Equity Financing
|
